Compare AEVA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | MGTX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2018 |
| Metric | AEVA | MGTX |
|---|---|---|
| Price | $10.20 | $9.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $29.00 | $27.75 |
| AVG Volume (30 Days) | ★ 1.4M | 900.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $78.97 | $314.19 |
| Revenue Next Year | $124.76 | N/A |
| P/E Ratio | ★ N/A | $7.51 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $8.83 | $6.62 |
| 52 Week High | $31.30 | $15.35 |
| Indicator | AEVA | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 31.78 |
| Support Level | N/A | $8.84 |
| Resistance Level | $16.49 | $10.06 |
| Average True Range (ATR) | 0.76 | 0.53 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 12.48 | 3.63 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.